Last reviewed · How we verify

NCT03121573

Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial

Completed NA Last updated 20 April 2017
What this trial tests

NA trial testing Duloxetine in Major Depressive Disorder in 30 participants. Completed in 17 January 2017.

Timeline
15 December 2014
Primary endpoint
26 September 2016
17 January 2017

Quick facts

Lead sponsorTaichung Veterans General Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Designsequential
Maskingnone
Primary purposehealth services research
Enrollment30
Start date15 December 2014
Primary completion26 September 2016
Estimated completion17 January 2017

Drugs / interventions tested

Conditions studied

Sponsor

Taichung Veterans General Hospital

Who can join

Adults 20 to 65, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to investigate the effects of duloxetine on improvement of brain cortical activity in patients suffering from major depressive disorder using near infrared spectroscopy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Duloxetine

Trials testing the same drug.

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

Other Taichung Veterans General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03121573.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing